UNSPSC 51343100: Antiviral pyrimidines

Antiviral drugs made from a family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms.

UNSPSC 51343100 Antiviral pyrimidines is a Class code that does not align with the recent state and local contract opportunities posted under it. The code's nominal scope covers a specific pharmaceutical compound class, yet the four recent opportunities solicited under this code involve naloxone procurement (opioid antagonist for overdose response), emergency medical and first aid supplies for fire rescue operations, direct-to-manufacturer prescription drug programs, and generic multi-source pharmaceuticals with over-the-counter products through cooperative purchasing. None of these solicitations concern antiviral pyrimidines as a product category. The mismatch suggests either a cataloging error in how opportunities were tagged to the UNSPSC code or use of the code as a catch-all for pharmaceutical and health-supply procurement more broadly within participating jurisdictions.

State and local issuing bodies posting under this code span county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), municipal fire departments (City of Tampa), and cooperative purchasing alliances serving multiple states (Minnesota Multistate Cooperative Purchasing Alliance). Recent activity is concentrated in Florida, Texas, Minnesota, and Oregon, with the Texas RFI representing exploratory market research rather than a formal competitive solicitation. Representative recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline; the City of Tampa's sealed-bid solicitation for 169 line items of medical and first aid supplies (estimated contract value $700,000.00) with a March 13, 2026 deadline and a 5% SLBE bid discount; and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products across multiple state and local facilities, due March 26, 2026, with awards effective July 1, 2026. The code shows no relevant recent activity aligned with its nominal antiviral pyrimidine scope.